Ivy League Study: Boosters, COVID-19 ‘Rebounds’ Fuel Skepticism of Federal Narratives

As the nation’s most powerful and twice-boosted infectious disease doctor battles a COVID-19 “rebound” two weeks after testing positive, new research from the public health schools at Harvard and Yale suggests the boosted fared worse against the first Omicron subvariant than the non-boosted.

The FDA is so alarmed by the “waning effectiveness” of boosters, whose formulation is still based on the ancestral Wuhan strain, that it asked manufacturers Thursday to add a “spike protein component” from the fourth and fifth Omicron subvariants to this fall’s boosters.

Read More

Pfizer Launches Trials to Test Booster COVID Shots in Knoxville, Nashville

Pfizer has launched trials in Knoxville and Nashville to test a third booster shot for the COVID-19 vaccine, marketed as an “updated version.” Alliance for Multispecialty Research (AMR) Knoxville’s Volunteer Research Group is conducting the Knoxville study, and Clinical Research Associates is conducting the Nashville study. Pfizer claimed in a press release earlier this month that a third dose of the COVID-19 vaccine would more effectively provide immunization, especially against the Delta variant.

Read More